Chunhui Medical Secures Tens of Millions in Pre-A Funding to Advance Non-Invasive Optical Molecular Quantitative Detection Platform for Breast Cancer

VCBeat has learned that Hefei Chunhui Mingzhi Medical Technology Co., Ltd. (“Chunhui Medical”) announced the completion of its Pre-A financing round, raising tens of millions of RMB. The round was led by the Hefei Zhonghe Oupu Medical Health Industry Fund, with co-investment from Shanghai Zhanchen Yangfan New Materials Co., Ltd., an affiliate of Youbo Capital.

The company was co-founded by Professor Chen Nanguang, an internationally renowned scientist in the field of laser imaging, and Peng Zhigang, who has many years of in-depth experience in the medical and pharmaceutical industry and possesses a highly complementary professional background. Professor Chen Nanguang, the Chief Scientist, is currently a Professor in the Department of Biomedical Engineering at the National University of Singapore. He isGlobalThe Original Inventor of the Laser Quantitative Mammography Technology Pathway. Professor Chen’s proprietary optical imaging technology enables “dual-modal imaging of structural and molecular functions,” representing the most advanced international platform for “non-invasive laser-based quantitative molecular detection.”

The funds raised in this round will be used for the research and development of an innovative “Diffuse Optical Quantitative Tomography System” protected by international patents. Compared with existing methods such as mammography and breast ultrasound, this system offers advantages including being painless, non-invasive, radiation-free, and not requiring contrast agent injection. It allows for repeated examinations, is unaffected by dense breast tissue, and does not rely on specialized technicians or operators. The system can effectively improve the detection rate of breast cancer while reducing rates of missed diagnoses and misdiagnoses. It fills the previous gap in suitable screening methods for women under 40 years old, particularly those with dense breasts, and is expected to become an important tool for evaluating prognosis and treatment efficacy in breast cancer, thereby reshaping the current landscape of breast cancer screening, diagnosis, and treatment protocols.

Chunhui Medical is located in the Aier Eye Hospital Innovation Base within the Hefei High-Tech Zone. The company specializes in the research, development, production, and sales of optical diagnostic products for breast cancer. Leveraging Laplace-domain diffuse optical tomography and spectroscopy technologies, Chunhui Medical provides medical institutions and health examination centers with cost-effective, user-friendly, highly sensitive, non-invasive, and radiation-free optical detection equipment and services for breast cancer. Additionally, the company offers comprehensive optical diagnostic solutions for breast cancer as part of the government’s “Two-Cancer Screening” program, safeguarding women’s breast health and contributing to the realization of the “Healthy China” vision.

Currently, the company holds 15 intellectual property rights, including core invention patents and software copyrights. Its core product, the DOBCIS Light-Scattering Breast Diagnostic System (Model: DOD-01), has obtained the Class II Medical Device Registration Certificate.

For this round of financing,Peng Zhigang, founder of Chunhui Medical, stated“Addressing unmet clinical needs and driving medical technological innovation are the core missions of Chunhui Medical. Guided by the principle of value-based healthcare, Chunhui Medical closely collaborates with clinical experts and gains deep insights into patient needs. Upholding a global perspective and pursuing internationally leading innovations, we partner with outstanding experts and scientists worldwide, striving to become a medical innovation enterprise that reveres life, promotes inclusive altruism, and harnesses technology for social good.”

Mr. Tao Yuequn, Chairman of Autek China Technology Co., Ltd. and Investment Committee Member of the Hefei Zhonghe Autek Medical Health Industry Fund, stated: “As a healthcare industry fund, we focus on outstanding global scientists and entrepreneurial teams, vigorously supporting the industrialization and commercialization of original core technologies and scientific achievements to meet rigid clinical demands. Chunhui Medical is an emerging enterprise in recent years that is ‘based on original hard-core technology, integrating medicine and engineering for industrial transformation’”’As an outstanding representative, we believe the company will continue to deliver internationally competitive products in the laser field.”

Pan Peng, General Manager of Shanghai Zhanchen Yangfan New Materials Co., Ltd. and Partner at Shenzhen Youbo Capitalstated: “Women’s health has always been a focal point of societal concern, as well as our”ofInvestment Highlights.Chunhui Medical’s scientists have pioneered the original invention ofGlobal Laser Quantitative Mammography Technology Pathway, CoreThe team also boasts years of in-depth expertise and accumulated experience in the field of laser imaging for medical applications.. We believe that,Chunhui Medical Will Safeguard the Health of More Women.”

Hefei Zhonghe Opu Medical Health Industry Fund (hereinafter referred to as “Zhonghe Opu”): A medical industry fund jointly established by Zhonghe Investment and the listed company Opu Kangshi (Stock Code: 300595). The management team possesses extensive experience in medical industry investment and the incubation of scientific and technological achievements. The fund focuses on investing in new therapies, new technologies, and innovative products within the medical field, and has completed investments and strategic layouts in more than ten high-quality medical enterprises.

Shenzhen Youbo Capital represents a strategic initiative by alumni investment networks from Peking University and the University of Electronic Science and Technology of China in the Greater Bay Area. Following its presence in the Beijing-Tianjin-Hebei region, the Yangtze River Delta, and the Chengdu-Chongqing economic circle, this core deployment in the Greater Bay Area aims to consolidate diverse resources and establish itself as an emerging force in the investment landscape.